Grace Therapeutics, Inc. Net Income (Loss) Attributable to Parent in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Grace Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to Q3 2025.
  • Grace Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$938K, a 72.7% increase year-over-year.
  • Grace Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$7.82M, a 32.6% increase year-over-year.
  • Grace Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$9.57M, a 25.6% increase from 2023.
  • Grace Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$12.9M, a 69.7% increase from 2022.
  • Grace Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$42.4M, a 332% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Grace Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$7.82M -$938K +$2.49M +72.7% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 -$10.3M -$3.36M -$745K -28.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-13
Q1 2025 -$9.57M $636K +$3.8M Jan 1, 2025 Mar 31, 2025 10-K 2025-06-23
Q4 2024 -$13.4M -$4.16M -$1.76M -73.8% Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-13
Q3 2024 -$11.6M -$3.43M -$159K -4.86% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 -$11.4M -$2.62M +$1.41M +34.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-13
Q1 2024 -$12.9M -$3.17M +$25.9M +89.1% Jan 1, 2024 Mar 31, 2024 10-K 2025-06-23
Q4 2023 -$38.8M -$2.39M +$1.5M +38.5% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-13
Q3 2023 -$40.3M -$3.27M +$1.66M +33.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$41.9M -$4.02M +$501K +11.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$42.4M -$29.1M -$25.2M -645% Jan 1, 2023 Mar 31, 2023 10-K 2024-06-21
Q4 2022 -$17.2M -$3.89M -$111K -2.94% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 -$17.1M -$4.93M -$5.91M -602% Jul 1, 2022 Sep 30, 2022 10-Q 2024-02-12
Q2 2022 -$11.2M -$4.52M -$1.41M -45.1% Apr 1, 2022 Jun 30, 2022 10-Q 2024-02-12
Q1 2022 -$9.82M -$3.9M +$1.74M +30.9% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-23
Q4 2021 -$11.6M -$3.78M -$558K -17.3% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 -$11M $981K +$7.13M Jul 1, 2021 Sep 30, 2021 10-Q 2023-02-14
Q2 2021 -$18.1M -$3.12M +$1.55M +33.2% Apr 1, 2021 Jun 30, 2021 10-Q 2023-02-14
Q1 2021 -$19.7M -$5.65M +$19.9M +77.9% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-21
Q4 2020 -$39.5M -$3.22M +$8.9M +73.4% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 -$48.4M -$6.15M +$15M +71% Jul 1, 2020 Sep 30, 2020 10-Q 2022-02-14
Q2 2020 -$63.5M -$4.67M +$4.18M +47.3% Apr 1, 2020 Jun 30, 2020 10-Q 2022-02-14
Q1 2020 -$67.6M -$25.5M +$13.9M +35.2% Jan 1, 2020 Mar 31, 2020 10-K 2020-06-29
Q4 2019 -$81.5M -$12.1M Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 -$21.2M Jul 1, 2019 Sep 30, 2019 10-Q 2021-02-09
Q2 2019 -$8.85M Apr 1, 2019 Jun 30, 2019 10-Q 2021-02-09
Q1 2019 -$39.4M Jan 1, 2019 Mar 31, 2019 10-K 2020-06-29

Grace Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$9.57M +$3.29M +25.6% Apr 1, 2024 Mar 31, 2025 10-K 2025-06-23
2023 -$12.9M +$29.6M +69.7% Apr 1, 2023 Mar 31, 2024 10-K 2025-06-23
2022 -$42.4M -$32.6M -332% Apr 1, 2022 Mar 31, 2023 10-K 2024-06-21
2021 -$9.82M +$9.86M +50.1% Apr 1, 2021 Mar 31, 2022 10-K 2023-06-23
2020 -$19.7M +$5.84M +22.9% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-21
2019 -$25.5M +$13.9M +35.2% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-22
2018 -$39.4M Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.